Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in particular amounts, for use in preventing and/or treating infections and/or inflammations of the lower respiratory tract and/or of the ear in an infant or a young child.
1. A method for reducing an incidence and/or severity of and/or treating an infection and/or inflammation of the lower respiratory tract and/or of the ear selected from the group consisting of pneumonia, bronchitis, bronchiolitis, otitis, otitis media and combinations thereof in an infant or a young child in need thereof, the method comprising administering to the infant or young child a nutritional composition comprising 2′-fucosyllactose (2′FL) as the only fucosylated oligosaccharide in the nutritional composition in a total amount of 0.85-1.3 g/L of the nutritional composition and/or in a total amount of 0.59-0.9 g/100 g of the nutritional composition on a dry weight basis; and lacto-N-neotetraose (LNnT) as the only N-acetylated oligosaccharide in the nutritional composition in a total amount of 0.45-0.75 g/L of the composition and/or in a total amount of 0.35-0.52 g/100 g of the nutritional composition on a dry weight basis, wherein the nutritional composition does not contain any sialylated oligosaccharide.
2. The method according to claim 1 , wherein the nutritional composition comprises at least another ingredient selected from the group consisting of galacto-oligosaccharides, fructo-oligosaccharides, xylooligosaccharides, inulin, polydextrose, sialic acid, fucose and combinations thereof.
3. The method according to claim 1 , wherein the nutritional composition further comprises at least one probiotic in an amount of from 10 3 to 10 12 cfu/g of the nutritional composition (dry weight).
4. The method according to claim 1 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, an infant cereal composition, a fortifier and a supplement.
5. The method according to claim 1 , wherein the infection and/or inflammation of the lower respiratory tract and/or of the ear has an origin selected from the group consisting of a bacterial origin, a viral origin, and an environmental origin.
6. The method according to claim 1 , wherein the 2′-fucosyllactose (2′FL) and the lacto-N-neotetraose (LNnT) are the only HMOs in the nutritional composition.
7. The method according to claim 1 , wherein the infant or the young child was born by C-section.